Vor Biopharma Files 8-K for Disclosures

TL;DR

Vor Bio filed an 8-K, standard procedure, no major news yet.

AI Summary

Vor Biopharma Inc. filed an 8-K on October 28, 2025, to report on Regulation FD disclosures and file financial statements and exhibits. The filing does not contain specific details about new events, financial results, or material agreements as of that date.

Why It Matters

This filing indicates Vor Biopharma is meeting its regulatory reporting obligations. Investors should look for subsequent filings for specific operational or financial updates.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• Vor Biopharma Inc. (company) — Registrant
• October 28, 2025 (date) — Date of Report
• 500 Boylston Street, Suite 1350 (address) — Principal Executive Offices
• Boston, Massachusetts (location) — Principal Executive Offices Location
• 02116 (zip_code) — Principal Executive Offices Zip Code

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob

Filing Documents

• vor-20251028.htm (8-K) — 42KB
• vor-ex99_1.htm (EX-99.1) — 35KB
• vor-ex99_1s1.jpg (GRAPHIC) — 143KB
• vor-ex99_1s2.jpg (GRAPHIC) — 711KB
• vor-ex99_1s3.jpg (GRAPHIC) — 261KB
• vor-ex99_1s4.jpg (GRAPHIC) — 295KB
• vor-ex99_1s5.jpg (GRAPHIC) — 343KB
• vor-ex99_1s6.jpg (GRAPHIC) — 343KB
• vor-ex99_1s7.jpg (GRAPHIC) — 353KB
• vor-ex99_1s8.jpg (GRAPHIC) — 277KB
• vor-ex99_1s9.jpg (GRAPHIC) — 338KB
• vor-ex99_1s10.jpg (GRAPHIC) — 168KB
• vor-ex99_1s11.jpg (GRAPHIC) — 290KB
• vor-ex99_1s12.jpg (GRAPHIC) — 277KB
• vor-ex99_1s13.jpg (GRAPHIC) — 399KB
• vor-ex99_1s14.jpg (GRAPHIC) — 306KB
• vor-ex99_1s15.jpg (GRAPHIC) — 312KB
• vor-ex99_1s16.jpg (GRAPHIC) — 317KB
• vor-ex99_1s17.jpg (GRAPHIC) — 298KB
• vor-ex99_1s18.jpg (GRAPHIC) — 318KB
• vor-ex99_1s19.jpg (GRAPHIC) — 214KB
• vor-ex99_1s20.jpg (GRAPHIC) — 334KB
• vor-ex99_1s21.jpg (GRAPHIC) — 315KB
• vor-ex99_1s22.jpg (GRAPHIC) — 333KB
• vor-ex99_1s23.jpg (GRAPHIC) — 139KB
• vor-ex99_1s24.jpg (GRAPHIC) — 271KB
• vor-ex99_1s25.jpg (GRAPHIC) — 225KB
• vor-ex99_1s26.jpg (GRAPHIC) — 267KB
• vor-ex99_1s27.jpg (GRAPHIC) — 381KB
• vor-ex99_1s28.jpg (GRAPHIC) — 296KB
• vor-ex99_1s29.jpg (GRAPHIC) — 115KB
• 0001193125-25-253636.txt ( ) — 12089KB
• vor-20251028.xsd (EX-101.SCH) — 24KB
• vor-20251028_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 28, 2025, Vor Biopharma Inc. hosted a webcast to discuss late-breaking 48-week Phase 3 clinical trial data from China for telitacicept in primary Sjgren's disease. A copy of the presentation used during the webcast is furnished as Exhibit 99.1. The information contained in this Current Report on Form 8-K, including Exhibit 99.1, attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjgren's Disease 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: October 28, 2025 By: /s/ Jean-Paul Kress Jean-Paul Kress Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR